Evidence map›Paper›PMID 35069190›Full record

ReviewFrontiers in pharmacology2021

theLiTE™: A Screening Platform to Identify Compounds that Reinforce Tight Junctions.

Teresa Lopes Gomes, Virgínia de Oliveira-Marques, Richard John Hampson, António Jacinto, Luciana Vieira de Moraes, Rui Gonçalo Martinho

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Teresa Lopes GomesThelial Technologies SA, Parque Tecnológico de Cantanhede, Cantanhede, Portugal.
Virgínia de Oliveira-MarquesThelial Technologies SA, Parque Tecnológico de Cantanhede, Cantanhede, Portugal.
Richard John HampsonThelial Technologies SA, Parque Tecnológico de Cantanhede, Cantanhede, Portugal.
António JacintoiNOVA4Health, Chronic Diseases Research Centre - CEDOC, NOVA Medical School, NMS, Universidade Nova de Lisboa, Lisbon, Portugal.
Luciana Vieira de MoraesThelial Technologies SA, Parque Tecnológico de Cantanhede, Cantanhede, Portugal.
Rui Gonçalo MartinhoThelial Technologies SA, Parque Tecnológico de Cantanhede, Cantanhede, Portugal.
Universidade Nova de Lisboa · PTUniversity of Algarve · PT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tight junctions (TJ) are formed by transmembrane and intracellular proteins that seal the intercellular space and control selective permeability of epithelia. Integrity of the epithelial barrier is central to tissue homeostasis and barrier dysfunction has been linked to many pathological conditions. TJ support the maintenance of cell polarity through interactions with the Par complex (Cdc42-Par-6-Par-3-aPKC) in which Par-6 is an adaptor and links the proteins of the complex together. Studies have shown that Par-6 overexpression delays the assembly of TJ proteins suggesting that Par-6 negatively regulates TJ assembly. Because restoring barrier integrity is of key therapeutic and prophylactic value, we focus on finding compounds that have epithelial barrier reinforcement properties; we developed a screening platform (

Indexed as

epithelial cellsmyricetinPAR-6polarity (cell)quercetintight junctions

Identifiers

PMID35069190
PMCPMC8771259
OpenAlexW4206328318

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.